For individuals with weak eyes, spectacles and eyeglasses are unquestionably a blessing. They allow you to walk without tripping over objects, read, and essentially just see what's in front of you. But they can also be a curse. It is very easy to forget them at home or in the car, they break easily, and Covid, masks have taught us that they fog up real easy, effectively blinding you. But what if you didn't have to wear those pesky glasses all the time? If you're living in the United States this is a possibility. The FDA (Food and Drug Administration) has recently approved an eye drop that can replace glasses.

Watch |&nbsp;WION Fineprint | US approves eye drops that could replace reading glasses

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/wion-fineprint-us-approves-eye-drops-that-could-replace-reading-glasses-497433/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

This drug is called Vuity and it claims to improve age-related near-vision. As per an Express.co.uk report, the eye drops need to be applied once every six hours and starts working within 15 minutes of application.

According to the report, the medication is a formulated form of the well-known compound known as&nbsp;pilocarpine, and the researchers have developed&nbsp;it to&nbsp;quickly adapt to the pH of the tear film.

Also read |&nbsp;<a href="https://www.wionews.com/world/how-much-alcohol-to-drink-at-what-age-the-lancet-study-reveals-497554" hreflang="en">How much alcohol to drink at what age? The Lancet study reveals</a>

Utilising the eye's natural ability to constrict the pupil, the drop enhances near vision while preserving far vision.

The drop is most helpful for people between the ages of 40 and 55, according to the researchers' analysis of two randomised control trials involving 750 participants.

Moreover, they did not suffer any severe adverse effects; however, a few patients did report minor headaches and eye redness.

(With inputs from agencies)

Watch WION LIVE HERE:

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

For individuals with weak eyes, spectacles and eyeglasses are unquestionably a blessing. They allow you to walk without tripping over objects, read, and essentially just see what's in front of you.

For individuals with weak eyes, spectacles and eyeglasses are unquestionably a blessing. They allow you to walk without tripping over objects, read, and essentially just see what's in front of you. But they can also be a curse. It is very easy to forget them at home or in the car, they break easily, and Covid, masks have taught us that they fog up real easy, effectively blinding you. But what if you didn't have to wear those pesky glasses all the time? If you're living in the United States this is a possibility. The FDA (Food and Drug Administration) has recently approved an eye drop that can replace glasses. Watch | WION Fineprint | US approves eye drops that could replace reading glasses This drug is called Vuity and it claims to improve age-related near-vision. As per an Express.co.uk report, the eye drops need to be applied once every six hours and starts working within 15 minutes of application. According to the report, the medication is a formulated form of the well-known compound known as pilocarpine, and the researchers have developed it to quickly adapt to the pH of the tear film. Also read | How much alcohol to drink at what age? The Lancet study reveals Utilising the eye's natural ability to constrict the pupil, the drop enhances near vision while preserving far vision. The drop is most helpful for people between the ages of 40 and 55, according to the researchers' analysis of two randomised control trials involving 750 participants. Moreover, they did not suffer any severe adverse effects; however, a few patients did report minor headaches and eye redness. (With inputs from agencies) Watch WION LIVE HERE: You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

US FDA approves new eye drops that can replace spectacles and fix near-vision

We have some great news for senior cats who wish to get a new lease on life, senior felines hoping to get a spring back in their step.

For the first&nbsp;time ever, the US Food and Drug Administration (FDA) has approved a monoclonal antibody drug for controlling pain associated with osteoarthritis in cats. It is also the first monoclonal antibody drug approved by the FDA for any animal species.

Also read |&nbsp;<a href="https://www.wionews.com/world/believe-it-or-not-rare-see-through-fish-colony-found-in-antarctica-444565">Believe it or not: Rare ‘see-through’ fish colony found in Antarctica</a>

During the pandemic, these lab-grown proteins had garnered headlines for preventing severe illness in high-risk people with Covid.

Wear and tear of the cartilage that cushions the ends of the bones leads to osteoarthritis. When the bones in a joint rub against each other, they cause pain and lessen movement, and occasionally cause bone spurs.

60 per cent of cats aged six and older and 90 per cent of cats older than 12 years are thought to suffer from this condition.

"Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats," said Steven Solomon, director of the FDA's Center for Veterinary Medicine, in a statement.

"But with longer lives come chronic diseases, such as osteoarthritis," he added.

Also Read:&nbsp;<a href="https://www.wionews.com/science/no-kidding-goldfish-actually-drove-a-vehicle-on-land-443297" hreflang="en">No kidding: Goldfish actually drove a vehicle on land</a>

New injectable drug 'Solensia' attaches itself to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.&nbsp;

The medicine's active ingredient 'frunevetmab' binds itself to NGF, which prevents pain signals from reaching the brain.

Due to the fact that cats cannot directly express their symptoms, researchers asked their owners about their animals' ability to jump onto furniture, use their litter box, or groom themselves, and compared their abilities with before they developed osteoarthritis.&nbsp;

The owners were then asked to assess their cats' responses after receiving treatment.&nbsp;

Watch |&nbsp;Gravitas: Hamas claims 'Killer Zionist Dolphin' killed their commando

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-hamas-claims-killer-zionist-dolphin-killed-their-commando-444252/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

During randomized clinical trials, cats in the treatment group performed better on assessments than those receiving placebos.

This medicine is injected subcutaneously by a veterinarian once a month and its side effects include vomiting, diarrhoea, injection site pain, scabbing on the head and neck, dermatitis and pruritus (itching).&nbsp;

However, the side effects were mild and did not require discontinuing the treatment.&nbsp;

(With inputs from agencies)

We have some great news for senior cats who wish to get a new lease on life, senior felines hoping to get a spring back in their step. For the first time ever, the US Food and Drug Administration (FDA) has approved a monoclonal antibody drug for controlling pain associated with osteoarthritis in cats.

We have some great news for senior cats who wish to get a new lease on life, senior felines hoping to get a spring back in their step. For the first time ever, the US Food and Drug Administration (FDA) has approved a monoclonal antibody drug for controlling pain associated with osteoarthritis in cats. It is also the first monoclonal antibody drug approved by the FDA for any animal species. Also read | Believe it or not: Rare ‘see-through’ fish colony found in Antarctica During the pandemic, these lab-grown proteins had garnered headlines for preventing severe illness in high-risk people with Covid. Wear and tear of the cartilage that cushions the ends of the bones leads to osteoarthritis. When the bones in a joint rub against each other, they cause pain and lessen movement, and occasionally cause bone spurs. 60 per cent of cats aged six and older and 90 per cent of cats older than 12 years are thought to suffer from this condition. "Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats," said Steven Solomon, director of the FDA's Center for Veterinary Medicine, in a statement. "But with longer lives come chronic diseases, such as osteoarthritis," he added. Also Read: No kidding: Goldfish actually drove a vehicle on land New injectable drug 'Solensia' attaches itself to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. The medicine's active ingredient 'frunevetmab' binds itself to NGF, which prevents pain signals from reaching the brain. Due to the fact that cats cannot directly express their symptoms, researchers asked their owners about their animals' ability to jump onto furniture, use their litter box, or groom themselves, and compared their abilities with before they developed osteoarthritis. The owners were then asked to assess their cats' responses after receiving treatment. Watch | Gravitas: Hamas claims 'Killer Zionist Dolphin' killed their commando During randomized clinical trials, cats in the treatment group performed better on assessments than those receiving placebos. This medicine is injected subcutaneously by a veterinarian once a month and its side effects include vomiting, diarrhoea, injection site pain, scabbing on the head and neck, dermatitis and pruritus (itching). However, the side effects were mild and did not require discontinuing the treatment. (With inputs from agencies)

Good news for senior cats: US FDA approves drug for arthritis in aged felines

fda-approves-new-drug

Fda Approves New Drug, News on Fda Approves New Drug, stories on Fda Approves New Drug, articles on Fda Approves New Drug, Fda Approves New Drug stories at Wion, Fda Approves New Drug news, Fda Approves New Drug latest news

fda approves-new-drug

US FDA approves new eye drops that can replace spectacles and fix near-vision

Good news for senior cats: US FDA approves drug for arthritis in aged felines